Dr. Peter Attia

And you could argue with a regulatory change in the FDA, if we said greater emphasis on safety to approval, greater emphasis on post-market surveillance for efficacy, we shift this thing a little bit. Now you could say at three years we're trending, you get a provisional approval, and now we're going to follow you.

And you could argue with a regulatory change in the FDA, if we said greater emphasis on safety to approval, greater emphasis on post-market surveillance for efficacy, we shift this thing a little bit. Now you could say at three years we're trending, you get a provisional approval, and now we're going to follow you.

There's an example like PaxLivid in my mind, you could argue maybe should have been pulled, maybe it wasn't as effective as it looked in the trials. And that doesn't mean they were wrong to approve it because it was any port in a storm. But after the fact, we could have been, oh, you know what? No harm, no foul. It was safe.

There's an example like PaxLivid in my mind, you could argue maybe should have been pulled, maybe it wasn't as effective as it looked in the trials. And that doesn't mean they were wrong to approve it because it was any port in a storm. But after the fact, we could have been, oh, you know what? No harm, no foul. It was safe.

And so maybe we do that for oncology.

And so maybe we do that for oncology.

Exactly. Ongoing.

Exactly. Ongoing.

This is across the board, not just in clinical trials.

This is across the board, not just in clinical trials.

I think that that is absolutely correct. On the nursing front, there's a huge demand, obviously. How much of this do you think of absent robotics? So robots can really change the game. I'm not close enough to that. Are you?

I think that that is absolutely correct. On the nursing front, there's a huge demand, obviously. How much of this do you think of absent robotics? So robots can really change the game. I'm not close enough to that. Are you?

Yeah. So I don't know how long until a robot is doing what a nurse is doing. But when you think of medical and chart reconciliation and things like that, is that where you think the greatest opportunity is?

Yeah. So I don't know how long until a robot is doing what a nurse is doing. But when you think of medical and chart reconciliation and things like that, is that where you think the greatest opportunity is?

So the Nobel Prize last year was awarded for protein folding, AI-driven analysis. Explain to people why that is significant. How much do you think that particular achievement is going to advance biotechnology and what remains ahead of it as far as even greater molecule selection?

So the Nobel Prize last year was awarded for protein folding, AI-driven analysis. Explain to people why that is significant. How much do you think that particular achievement is going to advance biotechnology and what remains ahead of it as far as even greater molecule selection?

This is how you even- This is figuring out what you're going to do.

This is how you even- This is figuring out what you're going to do.

Do you think this is the most important thing from a promise perspective that AI has brought to medicine since?

Do you think this is the most important thing from a promise perspective that AI has brought to medicine since?